Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Paramyxovirus Therapy
Researchers from Cleveland Clinic, Department of Molecular Genetics report recent findings in paramyxovirus therapy
April 2nd, 2008
A report, 'Inhibition of human parainfluenza virus type 3 infection by novel small molecules,' is newly published data in Antiviral Research. According to a study from the United States, "Human parainfluenza virus type 3 (HPIV3) is an important respiratory tract pathogen of infants and children. There are no vaccines or antivirals currently approved for prevention or treatment of HPIV3 infection." "Towards developing an antiviral therapy to combat HPIV3 infection, we have established a green fluorescent protein (GFP)-tagged HPIV3 infected-cell assay and used it for screening of a small molecule library obtained from ChemBridge Diver. Two novel small molecules (C5...
Source: Vaccine Weekly (2008-04-02)
|
